Profil
Jarvis Reagan is associated with Anocca AB, where he is the Chief Executive Officer & Director.
He founded Anocca AB in 2014.
Aktive Positionen von Jarvis Reagan
| Unternehmen | Position | Beginn |
|---|---|---|
Anocca AB
 Anocca AB Miscellaneous Commercial ServicesCommercial Services Anocca AB is a Swedish biopharmaceutical company that is developing next-generation T-cell immunotherapies for the treatment of solid tumors, autoimmune diseases, and infectious diseases. The company was founded in 2014 by Jarvis Reagan and is based in Sweden. The company is building libraries of novel T-cell immunotherapies that specifically target difficult-to-treat cancers and will be moving into clinical trials in 2024. Anocca has a fully integrated research and development infrastructure, underpinned by tailor-made advanced software solutions and in-house clinical manufacturing and process development facilities. Anocca has raised over USD 100 million in funding from leading Nordic investors and secured EUR 25 million in funding from the European Investment Bank in 2022. The company's team of over 90 employees operates from its state-of-the-art R&D and manufacturing facilities. Jarvis Reagan has been the CEO since 2014. | Gründer | 01.01.2014 |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
| Private Unternehmen | 1 |
|---|---|
Anocca AB
Anocca AB Miscellaneous Commercial ServicesCommercial Services Anocca AB is a Swedish biopharmaceutical company that is developing next-generation T-cell immunotherapies for the treatment of solid tumors, autoimmune diseases, and infectious diseases. The company was founded in 2014 by Jarvis Reagan and is based in Sweden. The company is building libraries of novel T-cell immunotherapies that specifically target difficult-to-treat cancers and will be moving into clinical trials in 2024. Anocca has a fully integrated research and development infrastructure, underpinned by tailor-made advanced software solutions and in-house clinical manufacturing and process development facilities. Anocca has raised over USD 100 million in funding from leading Nordic investors and secured EUR 25 million in funding from the European Investment Bank in 2022. The company's team of over 90 employees operates from its state-of-the-art R&D and manufacturing facilities. Jarvis Reagan has been the CEO since 2014. | Commercial Services |
